Ozempic is a once-weekly injectable prescription medication approved by the FDA to treat type 2 diabetes in adults. It belongs to a class of drugs called GLP-1 receptor agonists, and beyond blood sugar control, it carries two additional FDA-approved uses: reducing the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease, and protecting kidney function in adults with type 2 diabetes and chronic kidney disease.
How Ozempic Works in the Body
Ozempic contains the active ingredient semaglutide, which mimics a natural hormone your gut releases after eating. This hormone, called GLP-1, plays several roles in blood sugar regulation. When you inject Ozempic, it triggers three key effects: it prompts your pancreas to release more insulin when blood sugar is high, it signals the liver to stop dumping excess sugar into the bloodstream, and it slows the speed at which food leaves your stomach. That last effect is a big reason people feel fuller longer after meals and why nausea is such a common side effect early on.
Because semaglutide only boosts insulin when blood sugar is elevated, it carries a lower risk of causing dangerously low blood sugar compared to some older diabetes medications. The drug stays active in the body long enough to require just one injection per week.
Blood Sugar Control
The primary reason Ozempic is prescribed is to lower A1C, the measure of average blood sugar over the past two to three months. Across the clinical trial program that led to its approval, semaglutide reduced A1C by 0.6 to 1.6 percentage points compared to other treatments. That range depends on the dose and what it was tested against, but the upper end of that spectrum is a substantial improvement. For context, getting A1C below 7% is the target for most people with type 2 diabetes, and many patients start treatment well above that threshold.
Ozempic is meant to be used alongside diet and exercise, not as a replacement for them. It can be prescribed on its own or combined with other diabetes medications like metformin or insulin, depending on how well blood sugar is being managed.
Heart and Kidney Protection
Ozempic’s benefits extend beyond blood sugar. For adults who have both type 2 diabetes and established cardiovascular disease, the drug is approved to reduce the risk of heart attack, stroke, and cardiovascular death. These aren’t small effects for a population already at high risk of cardiac events.
The newest addition to Ozempic’s label involves kidney protection. A large clinical trial called FLOW found that semaglutide lowered the risk of major kidney disease events by 24% in people with type 2 diabetes and chronic kidney disease. That included a slower decline in kidney filtration rate, fewer patients progressing to kidney failure, and a 20% lower risk of death from any cause. Cardiovascular deaths dropped by 29% in the same trial. For people managing both diabetes and kidney disease, these results represent a meaningful shift in what the drug can offer beyond glucose control.
What About Weight Loss?
This is where things get complicated. Ozempic is not FDA-approved for weight loss. However, semaglutide at a higher dose (2.4 mg, marketed as Wegovy) is approved specifically for weight management. Ozempic’s maximum dose is 2 mg. Many people hear about Ozempic in the context of weight loss because doctors sometimes prescribe it off-label for that purpose, and because the two products share the same active ingredient.
Semaglutide-based medications can lead to roughly 15 to 20% weight loss on average, significantly more than older weight loss drugs. Results vary widely, though. About half of patients lose 20% or more of their starting weight, while roughly a third lose closer to 10%. Weight loss with Ozempic at its lower doses tends to be more modest than what the higher-dose Wegovy delivers. If weight management is your primary goal rather than diabetes treatment, Wegovy is the version designed and approved for that.
Dosing Schedule
Ozempic follows a gradual dose increase to minimize side effects. You start at 0.25 mg once weekly for four weeks. That initial dose isn’t really meant to control blood sugar; it’s about letting your body adjust. After four weeks, the dose increases to 0.5 mg weekly for another four weeks, then to 1 mg weekly as the standard maintenance dose. Some people may be prescribed up to 2 mg if they need additional blood sugar control.
The injection goes under the skin of the abdomen, thigh, or upper arm. You can take it on any day of the week, with or without food, as long as you keep the same day each week.
Common Side Effects
Gastrointestinal problems are by far the most frequent complaint. Nausea affects 15 to 23% of patients and is the side effect most likely to cause someone to consider stopping. Diarrhea occurs in 8 to 14% of patients and is typically mild to moderate. Vomiting, constipation, and stomach pain round out the list. These side effects tend to be worst during dose increases and often improve over time as the body adjusts.
Eating smaller meals, avoiding high-fat or greasy foods, and eating slowly can help manage nausea during the adjustment period. The gradual dose titration exists specifically to reduce these early digestive symptoms.
Important Safety Concerns
Ozempic carries a boxed warning, the FDA’s most serious safety label, regarding thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors at doses similar to those used in humans. Whether this risk applies to people remains unknown, but the concern is serious enough that Ozempic is completely off-limits for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2.
Signs to be aware of include a lump or swelling in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness. Ozempic has also been associated with inflammation of the pancreas (pancreatitis), gallbladder problems, and changes in vision in people with diabetic eye disease. The risk of low blood sugar increases if Ozempic is taken alongside insulin or medications that stimulate insulin release.
Ozempic vs. Wegovy
Both products contain semaglutide and are made by the same manufacturer, but they serve different purposes on paper. Ozempic is approved for type 2 diabetes management, cardiovascular risk reduction in diabetic patients, and kidney protection. Wegovy is approved for weight management in adults and children 12 and older, for a type of liver disease called MASH, and for cardiovascular risk reduction in adults with obesity or overweight and heart disease. Wegovy’s maximum dose is 2.4 mg compared to Ozempic’s 2 mg.
The distinction matters for insurance coverage. Many insurers will cover Ozempic for a diabetes diagnosis but won’t cover it for weight loss alone. Wegovy, conversely, may be covered under obesity treatment criteria. Your diagnosis and the specific FDA indication often determine which version your insurance will pay for.